Rochester Medical Center Received $3 Million Cancer Grant
The National Cancer Institute awarded funds to investigate how pancreatic cancer cells evade the immune system.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Should government grant funding prioritize basic disease research over immediate clinical testing?
The National Cancer Institute has awarded a $3 million grant to a University of Rochester Medical Center research team. The researchers aim to discover how pancreatic cancer cells spread and resist current immunotherapies by manipulating their internal circadian systems.
Why it matters
This research explores whether cancer cells use circadian rhythms to suppress immune signals, a mechanism that currently contributes to poor patient outcomes. Understanding these biological patterns could lead to new methods for preventing metastasis in aggressive cancers.
The National Cancer Institute grant totals $3 million to support the study of pancreatic cancer cell behavior. Currently, the five-year survival rate for patients diagnosed with pancreatic ductal adenocarcinoma stands at 13%.
The players
National Cancer Institute
This federal agency is part of the National Institutes of Health and serves as the primary government hub for cancer research.
University of Rochester Medical Center
This academic medical center in Rochester conducts medical research and provides specialized patient care.
The details
Researchers at the University of Rochester Medical Center are investigating how the Dec2 gene and circadian systems allow cancer cells to evade immune detection. By tracking the metastatic process at different times of the day, the team hopes to identify specific biological windows where immune intervention might be most effective.
Timeline
Researchers received a Wilmot pilot award to begin joint work in 2022.
The team received the $3 million grant on September 22, 2026.
Health Landscape
This project represents a new addition to the specialized research portfolio funded by the National Cancer Institute. It follows a shift in oncological study toward understanding how intrinsic cellular rhythms influence the effectiveness of modern immunotherapy.
This grant does not change current treatment options for local patients in Rochester at this time. However, the study provides a foundation for developing future therapies that may one day improve survival rates for those facing pancreatic ductal adenocarcinoma.
The takeaway
Advancing our knowledge of how cancer cells utilize circadian rhythms may eventually bridge a critical gap in current oncology treatments. Researchers emphasize that observing the timing of metastasis is essential for developing interventions that work in sync with human biology.
Further reading
Learn more about the latest research in this field by visiting the Cancer section.
Live Poll
Should government grant funding prioritize basic disease research over immediate clinical testing?
